Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72837
Title:
Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center.
Authors:
Board, Ruth E; Bruijns, C T P H; Pronk, A E; Ryder, W David J; Wilkinson, Peter M; Welch, Richard; Shanks, Jonathan H; Connolly, G; Slade, Richard J; Reynolds, K; Kitchener, Henry C; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
Current accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P= 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom. ruth.board@christie-tr.nwest.nhs.uk
Citation:
Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center., 16 Suppl 1:18-24 Int. J. Gynecol. Cancer
Journal:
International Journal of Gynecological Cancer
Issue Date:
2006
URI:
http://hdl.handle.net/10541/72837
DOI:
10.1111/j.1525-1438.2006.00308.x
PubMed ID:
16515562
Type:
Article
Language:
en
ISSN:
1048-891X
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBoard, Ruth E-
dc.contributor.authorBruijns, C T P H-
dc.contributor.authorPronk, A E-
dc.contributor.authorRyder, W David J-
dc.contributor.authorWilkinson, Peter M-
dc.contributor.authorWelch, Richard-
dc.contributor.authorShanks, Jonathan H-
dc.contributor.authorConnolly, G-
dc.contributor.authorSlade, Richard J-
dc.contributor.authorReynolds, K-
dc.contributor.authorKitchener, Henry C-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-07T15:32:01Z-
dc.date.available2009-07-07T15:32:01Z-
dc.date.issued2006-
dc.identifier.citationStage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center., 16 Suppl 1:18-24 Int. J. Gynecol. Canceren
dc.identifier.issn1048-891X-
dc.identifier.pmid16515562-
dc.identifier.doi10.1111/j.1525-1438.2006.00308.x-
dc.identifier.urihttp://hdl.handle.net/10541/72837-
dc.description.abstractCurrent accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P= 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required.en
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectResidual Canceren
dc.subjectOvarian Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshCA-125 Antigen-
dc.subject.meshCancer Care Facilities-
dc.subject.meshFemale-
dc.subject.meshGreat Britain-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshNeoplasm, Residual-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPrognosis-
dc.subject.meshProspective Studies-
dc.subject.meshSeverity of Illness Index-
dc.subject.meshSurvival Analysis-
dc.subject.meshTomography, X-Ray Computed-
dc.titleStage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom. ruth.board@christie-tr.nwest.nhs.uken
dc.identifier.journalInternational Journal of Gynecological Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.